high-risk pregnancy, preeclampsia
Conditions
Interventions
This is an open, randomized, controlled, two-arm clinical trial among women using magnesium sulfate who undergo vaginal delivery or cesarean section. Participants will be randomized through a draw us
Sponsors
Hospital da Mulher Professor Doutor José Aristodemo Pinotti da Universidade Estadual de Campinas
Universidade Estadual de Campinas
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women; aged 18 years or older; receiving magnesium sulfate at the standard dose (intravenously with a loading dose of 4 g, followed by a maintenance dose of 1 to 2 g/hour); with an indication for delivery by vaginal birth or cesarean section
Exclusion criteria
Exclusion criteria: Women ;under 18 years of age; who decline to participate in the study; with a concurrent diagnosis of sepsis or intra-amniotic infection/chorioamnionitis; whose magnesium sulfate maintenance dose is not between 1–2 grams per hour; who received uterotonic medication more than 5 minutes after delivery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Women receiving Carbetocin will present with a lower volume of blood loss compared to those receiving Oxytocin and the incidence of postpartum hemorrhage will be lower among women using Carbetocin compared to those using Oxytocin | — |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of severe maternal outcomes will be lower among women receiving Carbetocin compared to those receiving Oxytocin | — |
Countries
Brazil
Contacts
Public ContactAdriana Luz
Hospital da Mulher Professor Doutor José Aristodemo Pinotti da Universidade Estadual de Campinas
Outcome results
None listed